# US 2023/0402127 A1 · Machine learning-based variant effect assessment and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0402127 A1
- Document ID: US20230402127A1
- Status: Published application
- Kind: A1
- Application number: 18/021,377
- Filed: 2021-07-06
- Published: 2023-12-14
- Earliest claimed: 2020-08-21
- Assignees: Inari Agriculture Technology, Inc.
- Applicants: Inari Agriculture Technology, Inc.
- Inventors: Ross Everett ALTMAN; Giles HALL; Adam Patrick JOYCE; Karl Anton Grothe KREMLING; Michael Andreas KOCK
- Web page: https://patentgrep.com/patent/US20230402127A1

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G06N 3/084: Backpropagation, e.g. using gradient descent
- G16B 20/50: Mutagenesis
- G16B 40/20: Supervised data analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein are machine learning-based methods for assessing the combined impact of multiple genetic variants, as well as the uses of such methods for various applications, such as in synthetic biology, personalized medicine, agricultural breeding, and genetic engineering. Also provided herein are exemplar computer-readable storage media and electronic devices for performing such methods.

## Claims

### Claim 1

A method for assessing effects of genetic variants, comprising:
a) receiving a dataset of sequences from an input device,
wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects; and
c) displaying the predicted effect scores on a display device.

### Claim 2 (depends on 1)

The method of claim 1, wherein the model is trained by:
a) a pre-training task, comprising:
1) receiving a pre-training dataset comprising a plurality of batches of naturally occurring sequences;
2) inputting each batch of sequences into a language model, wherein the model is configured to output a pre-training set of semantic features; and
3) automatically updating the language model after each batch;
b) optionally, a fine-tuning task, comprising:
1) receiving a fine-tuning dataset comprising a plurality of batches of naturally occurring sequences,
wherein the fine-tuning dataset is a subset of the pre-training dataset, or a set of sequences that are related to the pre-training dataset by common ancestry, homology, or multiple sequence alignment;
2) inputting each batch of sequences into the language model, wherein the model is configured to output a fine-tuning set of semantic features; and
3) automatically updating the language model after each batch; and
c) a transfer learning task, comprising:
1) receiving a final training dataset comprising labeled sequences mapped to effects; and
2) training a neural network model based on the final training dataset, wherein the neural network model is configured to receive data corresponding to the pre-training set of semantic features and/or the fine-tuning set of semantic features, and output one or more effect scores.

### Claim 3 (depends on 1)

The method of claim 1, wherein the model is trained by:
a) receiving a training dataset of sequences, comprising a training reference sequence and a training primary genetic variant, wherein the training primary genetic variant has an effect on the reference sequence with respect to a metric of interest;
b) inputting the training dataset into a generative procedure configured to generate one or more training secondary genetic variants according to a random seed;
c) calculating a loss function, wherein the loss function maps the combined effect of the primary and secondary genetic variants and the effect of the reference sequence onto a quantitative error score;
d) accepting or rejecting the one or more training secondary genetic variants according to one or more predetermined acceptance criteria on the loss function;
e) updating the generative procedure by incorporating the accepted one or more training secondary genetic variants in a new round of additional training secondary genetic variants; and
f) repeating steps b) to e) until the loss converges to a minimum.

### Claim 4 (depends on 3)

The method of claim 3, wherein the true compensatory effect is obtained from a saturation mutagenesis analysis.

### Claim 5 (depends on 3)

The method of claim 3, wherein the loss function is a binary loss function.

### Claim 6 (depends on 3)

The method of claim 3, wherein the loss function is based on a distance metric.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, further comprising selecting one or more secondary genetic variants based on the effect scores.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, further comprising prioritizing one or more secondary genetic variants based on the effect scores.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, further comprising evaluating epistasis of one or more secondary genetic variants based on the effect scores.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, further comprising:
a) altering one or more of the secondary genetic variants in the genome of an organism;
b) identifying an impact of the alteration on an endophenotype, wherein the endophenotype is a quantifiable phenotype at a sub-organismal level that can be measured by a biochemical, gene expression, or protein level assay, or visually via microscopy; and
c) updating the model using the identified endophenotypic impact.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the genetic variant is an allele or a mutation as compared to the reference sequence.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the primary genetic variant is a deleterious genetic variant having a deleterious or disease-causing effect as compared to the reference sequence.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the primary genetic variant is a beneficial genetic variant having a beneficial or disease-preventing effect as compared to the reference sequence.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the dataset of sequences are clustered by sequence similarity.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the dataset of sequences are obtained from a sequence database.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sequence database is the UniRef database, the UniParc database, the UniProt database, the Pfam database, or the SwissProt database.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the dataset of sequences are DNA sequences, RNA sequences, or protein sequences.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the dataset of sequences are sequences from a single gene or a protein encoded thereby.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the dataset of sequences are sequences from a single gene family or a protein family encoded thereby.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the dataset of sequences are sequences from different genes or proteins encoded thereby, wherein the encoded proteins physically interact to form a complex.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the dataset of sequences are sequences from different components within a virus, an organelle, a cell, a tissue, an organ, or an organism.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the dataset of sequences are viral sequences, bacterial sequences, algal sequences, fungal sequences, plant sequences, animal sequences, human sequences, or sequences from a particular phylogenetic lineage.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the dataset of sequences are from one or more coronaviruses.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the dataset of sequences are from one or more cancer cells.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the effect is an effect at a molecular level, a cellular level, a sub-organismal level, or an organismal level.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the effect is an effect affecting an endophenotype selected from a group consisting of messenger RNA (mRNA) abundance, gene transcript splicing ratio, protein abundance, micro RNA (miRNA) or small RNA (siRNA) abundance, translational efficiency, ribosome occupancy, protein modification, metabolite abundance, allele specific expression (ASE), or visual trait measured at the sub-organismal level.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the effect is an effect affecting a protein property.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the effect is an effect affecting protein structure, protein conformation, protein molecular or cellular function, protein stability, protein solvent accessibility, enzymatic affinity, or enzymatic efficiency.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the effect is a collection of effects characterizing the state of a protein.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the effect is an effect affecting fitness of an organism.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the effect is interpretable to humans and/or machines.

### Claim 32

A method for designing a molecule with a desired effect, comprising:
a) receiving a dataset of sequences from an input device,
wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects;
c) displaying the predicted effect scores on a display device; and
d) designing a molecule based on the effect scores.

### Claim 33 (depends on 32)

The method of claim 32, further comprising synthesizing the designed molecule.

### Claim 34 (depends on 32, 33)

The method of any one of claims 32-33, wherein the effect of the designed molecule is stability, solubility, affinity, biological activity, bioavailability, a chemical property, a physical property, or a structural property.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32-34, wherein the designed molecule is a DNA molecule, an RNA molecule, or a protein molecule.

### Claim 36 (depends on 32, 33, 34, 35)

The method of any one of claims 32-35, wherein the designed molecule is a single stranded DNA (ssDNA) or a double stranded DNA (dsDNA).

### Claim 37 (depends on 32, 33, 34, 35, 36)

The method of any one of claims 32-36, wherein the designed molecule is a messenger RNA (mRNA), a transfer RNA (tRNA), a ribosomal RNA (rRNA), a small RNA (sRNA), or a guide RNA (gRNA).

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32-37, wherein the designed molecule is an antibody, a contractile protein, an enzyme, a hormonal protein, a structural protein, a storage protein, or a transport protein.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 32-38, wherein the designed molecule is a viral molecule, a bacterial molecule, an algal molecule, a fungal molecule, a plant molecule, an animal molecule, or a human molecule.

### Claim 40 (depends on 39)

The method of claim 39, wherein the designed molecule is a virus protein.

### Claim 41 (depends on 40)

The method of claim 40, wherein the virus protein is a protein from a coronavirus.

### Claim 42 (depends on 41)

The method of claim 41, wherein the coronavirus is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is the causal agent for the infectious disease coronavirus disease 2019 (COVID-19).

### Claim 43

A method for providing personalized and probabilistic information for a patient, comprising:
a) receiving a dataset of sequences associated with a patient from an input device, wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects;
c) displaying the predicted effect scores on a display device; and
d) assisting in selection of one or more medical choices specific to the patient based on the effect scores.

### Claim 44 (depends on 43)

The method of claim 43, wherein the attribute associated with the patient is selected from the group consisting of genetic profile, predisposition or response to a disease, and response to a treatment.

### Claim 45 (depends on 44)

The method of claim 44, wherein the genetic profile is from one or more cancer tumors of the patient.

### Claim 46 (depends on 44)

The method of claim 44, wherein the disease is selected from the group consisting of cancer, obesity, hypertension, a cardiovascular disease, an infectious disease, an autoimmune disease, a genetic disease, a liver disease, insulin resistance, Crohn's disease, dementia, Alzheimer's disease, cerebral infarction, hemophilia, viral hepatitis, sickle cell disease, multiple sclerosis, and muscular dystrophy.

### Claim 47 (depends on 44)

The method of claim 44, wherein the treatment is selected from the group consisting of drug administration, chemotherapy, radiation therapy, immunotherapy, and gene therapy.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the one or more medical choices are selected from the group consisting of prognosis, diagnosis, treatment, intervention, and prevention.

### Claim 49

A method for predicting resistance of a pathogen to an anti-pathogen treatment, comprising:
a) receiving a dataset of sequences associated with a pathogen from an input device, wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects,
wherein the effect affects an attribute associated with the pathogen having resistance to an anti-pathogen treatment; and
c) displaying the predicted effect scores on a display device, corresponding to the predicted resistance of the pathogen to the anti-pathogen treatment.

### Claim 50 (depends on 49)

The method of claim 49, wherein the pathogen is a virus, a prion, a viroid, a bacterium, a fungus, a protozoan, or a parasite.

### Claim 51 (depends on 49, 50)

The method of any one of claims 49-50, wherein the attribute associated with the pathogen is selected from the group consisting of nucleic acid replication, DNA integration into a host genome, gene expression, protein synthesis, metabolism, cell membrane synthesis, cell wall synthesis, and peptidoglycan biosynthesis.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49-51, wherein the anti-pathogen treatment is administering a drug selected from the group consisting of an antiviral, an antibacterial, an antibiotic, an antifungal, an antiparasitic, and a pesticide.

### Claim 53 (depends on 49, 50, 51, 52)

The method of any one of claims 49-52, wherein the pathogen is Neisseria gonorrhea and the anti-pathogen treatment is administration of ciprofloxacin or ceftriaxone.

### Claim 54

A method for identifying targets for genetically improving a trait in an organism, comprising:
a) receiving a dataset of sequences associated with an organism from an input device, wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects, and
wherein the effect affects an attribute associated with a trait of the organism; and
c) displaying the predicted effect scores on a display device, corresponding to the targets for genetically improving the trait in the organism.

### Claim 55 (depends on 54)

The method of claim 54, further comprising selecting one or more of the identified targets for genetic improvement of the organism.

### Claim 56 (depends on 54, 55)

The method of any one of claims 54-55, further comprising selecting an organism with the improved trait.

### Claim 57 (depends on 54, 55, 56)

The method of any one of claims 54-56, wherein the genetic improvement is achieved by conventional breeding.

### Claim 58 (depends on 54, 55, 56, 57)

The method of any one of claims 54-57, wherein the genetic improvement is achieved by a transgenic technology or a genome editing technology.

### Claim 59 (depends on 58)

The method of claim 58, wherein the genome editing technology is a base editing technology using a DNA base editor or an RNA base editor.

### Claim 60 (depends on 54, 55, 56, 57, 58, 59)

The method of any one of claims 54-59, wherein the genome editing is achieved by a clustered regularly interspersed short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN) system, or a zinc finger nuclease (ZFN) system.

### Claim 61 (depends on 60)

The method of claim 60, wherein the genome editing is achieved by coupling with a recombination system.

### Claim 62 (depends on 61)

The method of claim 61, wherein the recombination system is a lambda phage derived recombination (lambda Red) system.

### Claim 63 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 54-62, wherein the organism is maize, wheat, barley, oat, rice, soybean, oil palm, safflower, sesame, tobacco, flax, cotton, sunflower, pearl millet, foxtail millet, sorghum, canola, cannabis, a vegetable crop, a forage crop, an industrial crop, a woody crop, or a biomass crop.

### Claim 64 (depends on 63)

The method of claim 63, wherein the trait is yield, overall fitness, biomass, photosynthetic efficiency, nutrient use efficiency, heat tolerance, drought tolerance, herbicide tolerance, or disease resistance.

### Claim 65 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the organism is cattle, sheep, goat, horse, pig, chicken, duck, goose, rabbit, or fish.

### Claim 66 (depends on 65)

The method of claim 65, wherein the trait of the organism is growth rate, feed use efficiency, meat yield, meat quality, milk yield, milk quality, egg yield, egg quality, wool yield, or wool quality.

### Claim 67 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

An organism genetically improved by the method of any one of claims 54-66.

### Claim 68

A method for identifying genetic variants as alternative candidates for use as targets that are more easily accessible by a transgenic technology or a genome editing technology, comprising:
a) receiving a dataset of sequences associated with an organism from an input device, wherein the dataset of sequences comprises a reference sequence, a primary genetic variant of the reference sequence, and two or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects; and
c) displaying the predicted effect scores on a display device, corresponding to the genetic variants as alternative candidates for use as more accessible targets in genome editing.

### Claim 69 (depends on 68)

The method of claim 68, further comprising producing the genetic variants identified as alternative candidates targets in genome editing.

### Claim 70 (depends on 68, 69)

The method of any one of claims 68-69, wherein the genome editing is achieved by a base editing technology using a DNA base editor or an RNA base editor.

### Claim 71 (depends on 70)

A base editing technology according to the method of claim 70.

### Claim 72

A non-transitory computer-readable storage medium storing one or more programs, the one or more programs comprising instructions, which when executed by one or more processors of an electronic device having a display, cause the electronic device to:
a) receive a dataset of sequences from an input device,
wherein the dataset of sequences comprise a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically input the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects; and
c) display the predicted effect scores on a display device.

### Claim 73 (depends on 72)

The computer-readable medium of claim 72, wherein the model is a discriminative model or a generative model.

### Claim 74

An electronic device, comprising:
a display;
one or more processors;
a memory; and
one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for:
a) receiving a dataset of sequences from an input device,
wherein the dataset of sequences comprise a reference sequence, a primary genetic variant of the reference sequence, and one or more secondary genetic variants in the reference sequence;
b) automatically inputting the dataset of sequences to a trained machine-learning model to predict one or more effect scores,
wherein the model is configured to output one or more effect scores corresponding to the probabilities of one or more secondary genetic variants having a compensatory effect to the primary genetic variant, or the magnitudes of said effects; and
c) displaying the predicted effect scores on a display device.
